Rare diseases
Investigational molecules
Locations
Back to Germany30 clinical trials in Ratingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
GermanyStudy of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it
GermanyStudy of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines
GermanyGermanyPhase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease
GermanyGermanyA Study of Tulisokibart for Adults with Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)
GermanyStudy on the Safety and Effects of NSC001 and Trospium Chloride for Patients with Mild to Moderate Alzheimer's Disease
GermanyPhase 3 Randomized, Double‑Blind Study of Telitacicept versus Placebo for Efficacy and Safety in Adults with Active Primary Sjögren’s Disease
GermanyStudy of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications
GermanyStudy of Orforglipron in Overweight Adults at Risk of Developing Obesity‑Related Complications or Class 1 Obesity
GermanyA Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease
GermanyThe busiest research cities in the country
What the registry says about research in the country
Multiple clinical trials focusing on psoriatic arthritis (PsA) treatment innovations, including studies of novel therapies like zasocitinib, bimekizumab, and guselkumab for managing active disease symptoms.
Research aims to improve treatment options and reduce symptoms in patients with varying disease severity levels.
Ongoing investigations into rheumatoid arthritis treatments, featuring comparative studies of medications like upadacitinib and adalimumab, with particular focus on patients who have had inadequate response to previous treatments.
These studies aim to expand therapeutic options for patients with moderate to severe disease.
Comprehensive research into various inflammatory conditions including polymyalgia rheumatica and axial spondyloarthritis, evaluating new treatment approaches and maintenance therapies.
Focus on developing sustainable long-term treatment solutions for chronic inflammatory conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
